Virtual symposium “Hot topics and challenges in SBRT for oligometastatic disease”

Virtual Event

EORTC is pleased to invite you to a virtual symposium organized by the EORTC & ESTRO OligoCare project. Esteemed speakers will discuss the latest evidence and clinical trials in the field of oligometastatic disease, sharing the latest insights gained from the OligoCare cohort.

Additionally, we will discuss the TwiCs methodology’s application in radiation oncology, specifically addressing the “optimal” fractionation for SABR in patients with oligometastases. We will explore the scientific and operational aspects of the upcoming TwiCs research question: “OligoCare TwiCs comparing acute toxicity in single-fraction vs multiple-fraction SBRT for metastasis-directed treatment.”

Join us on:
30 January 2024
From 16:00 to 18:00 CET


Daniela Greto
Giulio Francolini
Chiaojung Jillian Tsai
David Palma
Shankar Siva
Piet Ost
Matthias Guckenberger
Sarah Nuyens


Timeslot Title of presentation Speaker
16:00-16:05 WELCOME Piet Ost & Matthias Guckenberger
16:05-16:15 Current status of OligoCare enrolment and data quality Sarah Nuyens (EORTC PM) & Matthias Guckenberger
16:15-16:35 Quality-of-Life after SBRT for oligometastatic disease – results of OligoCare Daniela Greto
16:35-16:55 Latest randomised evidence: ARTO trial for Oligometastatic Castrate-Resistant Prostate Cancer Giulio Francolini
16:55-17:15 Latest randomised evidence: CURB trial for oligoprogressive NSCLC and breast cancer Chiaojung Jillian Tsai
17:15-17:35 Latest randomised evidence: STOP trial for oligoprogressive cancer patients David Palma
17:35-17:55 Experiences and evidence for single-fraction SBRT Shankar Siva
17:55-18:00 CLOSURE Piet Ost & Matthias Guckenberger

EORTC and ESTRO Collaboration

E²RADIatE is a joined collaboration of two international not-for-profit organisations:

The European Organisation for Research and Treatment of Cancer (EORTC) is Europe’s leading multidisciplinary clinical cancer research organisation, which unites research experts worldwide to define better treatments for cancer patients and improve their survival and quality of life.

The European Society for Radiotherapy and Oncology (ESTRO) is a scientific non-profit organisation whose ambition is to further reinforce radiation oncology as a core partner in multidisciplinary cancer care and to guarantee accessible and high-value radiation therapy for all cancer patients who need it.

The SPRINT TwiCs is in the OligoCare cohort of E²-RADIatE, which is generously supported by Walgreens Boots Alliance.

Next events

  • The 10+1 Santorini Conference


  • EACR Annual Congress 2024

    Rotterdam, Netherlands

  • Clinical Trial Statistics for Non-Statisticians

    Brussels, BE

  • EORTC Leukemia Group Spring Meeting 2024

    Madrid, ES

  • 24th Workshop on Methods in Clinical Cancer Research (MCCR)

    Sint Michielgestel, Netherlands